Ethical Alternatives to Drug Testing

𝟵𝟬% 𝗼𝗳 𝗱𝗿𝘂𝗴𝘀 𝗳𝗮𝗶𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. Despite rigorous testing, the pharmaceutical industry continues to grapple with a high failure rate. It’s a decades old problem that persists. The disconnect between animal models and human biology has led to inefficiencies and ethical concerns. It’s a moral tug-of-war that once seemed unresolvable medical progress often came at the cost of animal welfare. More than 115 million animals are estimated to be used in drug testing globally each year. Shockingly, 95% of drugs shown to be safe and effective in animal tests fail in human trials. And nearly 99% of animals used in scientific experiments are not protected by federal animal welfare laws. 𝗦𝗼 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝘀𝗮𝗳𝗲, 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗱𝗿𝘂𝗴𝘀 𝗳𝗼𝗿 𝗵𝘂𝗺𝗮𝗻𝘀 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗲𝗹𝘆𝗶𝗻𝗴 𝗵𝗲𝗮𝘃𝗶𝗹𝘆 𝗼𝗻 𝗮𝗻𝗶𝗺𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴? Scientists at Harvard University introduced a groundbreaking idea: creating replicas of human organs on tiny lab chips. Just as we’ve downsized from massive storage units to microchips in our devices, could we now miniaturize organs onto chips? I was thrilled to read about this development. I’ve often wondered about the moral cost of inducing disease in other living beings for the sake of our health. 𝗢𝗿𝗴𝗮𝗻𝘀-𝗼𝗻-𝗰𝗵𝗶𝗽𝘀 (𝗢𝗼𝗖𝘀) are essentially tiny 3D cell cultures that act as a bridge between traditional animal testing and the complexities of human biology. OoC models consist of miniature tissue systems grown within microfluidic chips, lined with living human cells. These chips simulate human physiology, enabling drug development, disease modelling, and personalized medicine. With OoCs, researchers can create more accurate and efficient models for testing human drugs reducing the likelihood of ineffective or harmful treatments. By mimicking a cell’s microenvironment on a chip, we can study genetic factors, explore new treatment avenues for complex conditions, and even address rare diseases with limited sample sizes. OoCs also enable biomaterial testing, helping evaluate the biocompatibility of materials used in medical devices. Recently, a firm called 𝗘𝗺𝘂𝗹𝗮𝘁𝗲 tested a Liver-on-a-Chip device with 27 drugs that had passed animal trials but were toxic to humans. The chip accurately flagged 87% of these harmful compounds. I'm truly excited about the integration of tissue engineering and microfabrication to advance our understanding of human biology ethically and effectively. I hope to see a future where research and commercial applications in this space grow rapidly, helping us build a more humane and progressive health tech ecosystem one where millions of animals no longer have to suffer in the name of human progress. Watch this video by Harvard to learn more. #healthcare #technology #healthtech #innovation 

🚀 𝐌𝐨𝐯𝐢𝐧𝐠 𝐛𝐞𝐲𝐨𝐧𝐝 𝐚𝐧𝐢𝐦𝐚𝐥 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 In April the #FDA announced a phased roadmap to phase out mandatory animal testing for monoclonal antibodies and other drugs, a move towards safer, faster, and more human-relevant methods 𝗪𝗵𝗮𝘁’𝘀 𝗳𝗶𝗹𝗹𝗶𝗻𝗴 𝘁𝗵𝗲 𝗴𝗮𝗽? 🖥️𝗔𝗜 & 𝗰𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 - simulating drug distribution and toxicity across virtual patient populations. 🫁𝗢𝗿𝗴𝗮𝗻-𝗼𝗻-𝗮-𝗰𝗵𝗶𝗽 - micro-engineered systems that replicate human organs using real human cells. Think liver-on-a-chip to predict DILI or lung-on-a-chip for inhaled drug safety. 🧫𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱𝘀 & 𝟯𝗗 𝘁𝗶𝘀𝘀𝘂𝗲𝘀 — mini-organs built from stem cells, used to study everything from oncology to GI diseases. 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 🤔: 🐭Reduces reliance on animal studies (and the ethical + cost implications) ✅Offers more accurate human safety signals 💊Accelerates drug development timelines and lowers R&D costs 🔍 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝘀𝗵𝗶𝗳𝘁 𝗶𝘀 𝗮 𝘁𝗶𝗽𝗽𝗶𝗻𝗴 𝗽𝗼𝗶𝗻𝘁: 1️⃣𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘂𝗽𝗽𝗼𝗿𝘁: FDA is offering streamlined reviews for strong non-animal data 2️⃣𝗘𝘁𝗵𝗶𝗰𝗮𝗹 & 𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰𝗮𝗹: avoids costly primate studies, meets rising ethical standards. 3️⃣𝗛𝘂𝗺𝗮𝗻-𝗰𝗲𝗻𝘁𝗿𝗶𝗰: Animal models fail to predict human outcomes over 90% of the time, while NAMs promise much better translational relevance. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗪𝗮𝘆: ✅ #Organonchip: 🔹Emulate, Inc. - liver, lung, kidney, brain & intestine chips 🔹CN Bio - liver-on-chip for metabolic & toxicity studies 🔹MIMETAS - OrganoPlate®, scalable 3D co-cultures & perfusion 🔹Hesperos Inc. - Human-on-a-Chip® linking multiple organ systems 🔹TissUse GmbH - multi-organ microfluidic chips 🔹28bio (AxoSim) - brain & nerve-on-chip platforms ✅ #Organoids & #3Dtissues: 🔹STEMCELL Technologies -  kits & media for intestinal, lung, brain organoids 🔹Crown Bioscience -organoid CRO services 🔹InSphero - 3D microtissues for liver, pancreas & cancer 🔹DefiniGEN - hepatocyte & pancreatic organoids from iPSCs. #AI & #insilico: 🔹Insilico Medicine - AI target discovery + toxicity prediction 🔹Certara - PBPK & biosimulation software 🔹Simulations Plus, Inc. - ADME & PK/PD predictive tools 🔹Aitia - causal AI models for disease simulation 🔹Toxys - in vitro genotoxicity + AI analytics ⚠️ 𝗪𝗵𝗮𝘁’𝘀 𝗻𝗲𝘅𝘁? Regulators like the FDA are encouraging sponsors to submit data from these systems as part of INDs. It’s no longer a futuristic idea — it’s becoming standard practice to integrate NAMs alongside or even instead of certain animal studies. Of course, challenges remain: validating these systems, aligning global regulators, and ensuring models truly capture patient variability. But the trajectory is clear. 💬 𝗪𝗵𝗶𝗰𝗵 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝘁𝗵𝗶𝘀 𝘀𝗽𝗮𝗰𝗲 𝗮𝗿𝗲 𝘆𝗼𝘂 𝘄𝗮𝘁𝗰𝗵𝗶𝗻𝗴? Drop a comment — always keen to discover new names in this space!

Exciting news for India’s pharmaceutical future! 🌱 A new multi-stakeholder report reveals that non-animal testing methods (NAMs) could slash drug development timelines by more than half and cut costs by up to 70-90%, all while fully meeting global regulatory standards. The report — “Landscape Analysis on Alternatives to Animal Testing for Drug Development in India” — is a collaborative effort by Dr. Reddy’s Laboratories, inStem (DBT), Humane World for Animals India, and the Animal Law & Policy Network. Key takeaways: • Animal studies often add limited scientific value, especially for generics, biologics, and biosimilars, yet drive up time and cost. • Despite extensive animal testing, only 10-14% of drugs entering human trials ultimately gain approval. • Advanced NAMs like organ-on-chip systems, lab-grown human tissues, and AI-powered models better predict human responses and reduce late-stage failures. • The biggest impact? Biosimilars, where shifting to human-relevant methods is transforming economics globally. As DCGI Rajeev Raghuvanshi rightly noted, scientific progress now allows us to rethink safety and efficacy assessment without compromising patient outcomes. This isn’t just about ethics — it’s about smarter, faster, more cost-effective innovation that strengthens India’s position as the pharmacy of the world. Time for the industry to accelerate adoption of NAMs and lead the global shift. #PharmaInnovation #NonAnimalTesting #DrugDevelopment #Biosimilars #IndiaPharma #RegulatoryScience #OrganOnChip #SustainableScience

GOODBYE ANIMAL TESTING Big news from the FDA: They're starting to phase out animal testing requirements for monoclonal antibodies and other biologics. HUGE DEAL for science, ethics, and innovation. For decades, animal testing has been a regulatory bottleneck in drug development. Not always predictive. Not always necessary. Very expensive. Often cruel. We have better tools now. The FDA is now acknowledging that. This shift stems from the 2022 FDA Modernization Act, which for the first time allows non-animal alternatives like computational models, organ-on-a-chip systems, and advanced in vitro assays. The focus now is monoclonal antibodies (mAbs), the engine behind many of the most important therapies in cancer, autoimmune disease, and infectious disease. The FDA just released new draft guidance: 🧪 Removing routine animal tests for mAbs targeting non-human antigens 🧠 Encouraging case-by-case waivers for other biologics 👀 Eyeing “stepwise” expansion of non-animal approaches This isn’t just a policy update. It’s a signal. The regulatory state is catching up to the science. And that opens the door to faster, safer, and more ethical drug development. The downstream effect? 💊 Cheaper drugs 🐭 Fewer animals used ⚡️ Faster approvals 🧠 More accurate models of human biology The old dogma: “We have to test it in animals.” The new ethos: “We should test it in systems that work.” That means leveraging AI, synthetic biology, and human-relevant models.

🚀 Towards an Animal-Free Future in Drug Safety Testing We are pleased to share our new publication in Biofabrication! Our study introduces a fully human, animal-free Liver-on-Micropillar platform — a miniaturized, 3D-bioprinted liver model designed for high-throughput assessment of drug-induced liver injury (DILI). With recent initiatives by the FDA and major pharmaceutical companies such as Merck to reduce reliance on animal testing, there is a growing need for human-relevant alternatives in preclinical safety evaluation. Using our platform, we were able to correctly classify 10 reference compounds with 90% accuracy regarding their hepatotoxicity — outperforming traditional animal studies. This demonstrates that bioprinted human organ models can provide more predictive and ethically responsible tools for biomedical research and drug development. This work contributes to the broader goal of advancing non-animal methodologies that are scientifically robust, scalable, and aligned with regulatory and ethical progress. 📄 Read the full paper: Ali et al., Biofabrication (2025), “Liver-on-Micropillar: a humanized, animal-free platform for high-throughput assessment of drug-induced liver injury” https://lnkd.in/ezF-AsFW The video shows the creation of our micropillar system by bioprinting.

The Mouse Trap: Why a "Cure" in Rodents Is Often a Dead End for Humans The recent breakthrough from the Spanish National Cancer Research Centre (CNIO) has sparked global hope by completely eliminating pancreatic tumors in mice using a revolutionary triple-drug therapy. Led by Dr. Mariano Barbacid, the team utilized a combination of daraxonrasib, afatinib, and the experimental compound SD36 to make aggressive tumors vanish entirely. However, this scientific victory is built upon a foundation of profound ethical and biological complexity: the deliberate induction of terminal illness in sentient beings. To study the disease, these "oncomice" are first genetically engineered or injected with human cancer cells to ensure they develop debilitating tumors, a practice that critics argue is an unethical violation of animal rights. The ultimate ethical tension lies in the failure of translation between species; despite decades of "curing" cancer in rodents, the success rate for translating these results to human trials is less than 10%. As the scientific community acknowledges these limitations, a shift is occurring toward New Approach Methodologies (NAMs) that prioritize human biology over animal models. At the forefront is organ-on-a-chip (OoC) technology, which utilizes microfluidic devices to house living human cells. These chips, such as those developed by Emulate Bio, recreate the physical environment of an organ—including blood flow and mechanical strain—to predict drug responses with far greater accuracy than a mouse's body. Complementing these chips are patient-derived organoids, which are three-dimensional "mini-tumors" grown directly from a patient’s own tissue. As noted in research published via Nature, these models act as a biological mirror, allowing for precision testing of drug efficacy without an animal intermediary. This technological suite was further validated by the FDA Modernization Act 2.0, which officially removed the federal mandate for animal testing if alternative methods prove sufficient. While the Spanish team's results offer a beacon of hope for patients, the future of oncology lies in these human-centric models that aim to eliminate both the disease and the moral tax of the lives sacrificed to find a cure.

FDA pushes to replace animal testing in early drug development The FDA has issued new draft guidance encouraging drug developers to move away from traditional animal studies and adopt New Approach Methodologies (NAMs) — including AI-driven simulations, organ-on-chip systems, and human-derived organoids. This is more than a policy tweak — it’s a signal of where drug development is heading. 👇 ✅ Benefits More human-relevant data 🧬 Animal models often fail to predict human outcomes — NAMs could improve translation. Faster development timelines ⚡ AI and in vitro systems can significantly accelerate early-stage screening. Cost reduction 💰 Lower reliance on expensive animal studies = leaner R&D spend. Ethical progress 🐾 Reduced use of animal testing aligns with growing societal and regulatory expectations. ⚠️ Drawbacks Validation gap 📉 Not all NAMs are fully validated across therapeutic areas. Regulatory uncertainty 📑 Despite guidance, global alignment (FDA vs EMA, etc.) is still evolving. Technology limitations 🧪 Complex systemic responses (e.g. immune interactions) are still hard to replicate. ⚠️ Risks Over-reliance on immature tech 🤖 Premature adoption without robust validation could increase failure rates later. Fragmented adoption 🌍 Companies operating globally may face conflicting regulatory expectations. Talent & capability gap 👩🔬 Shift requires new skillsets (AI, bioengineering, computational biology). 📊 Impact on Industry Biotech & Pharma: Rethink preclinical strategies and investment allocation CDMOs & CROs: Need to expand capabilities into NAMs and digital platforms Investors: Increased focus on companies leveraging AI & human-relevant models Patients: Potentially faster access to safer, more effective therapies 🧠 Verdict This is a structural shift, not a trend. While animal models won’t disappear overnight, the direction is clear: Future drug development will be more human-centric, data-driven, and technology-enabled Those who adapt early will gain a speed, cost, and innovation advantage. Those who don’t risk falling behind. Symptome #FDA #DrugDevelopment #Biotech

Especially for ALL THE VISIONARY LEADERS. If you’re Leading a next-gen therapeutic company or Building AI, cell-based, or tissue engineering platforms, working with rare diseases, personalized medicine, or 3D-printed organoids - You are now operating in a world where innovation isn’t just encouraged—it’s now the standard. 🔍 The agency is calling this a “paradigm shift” because it’s not just regulatory reform—it’s a fundamental transformation of how drugs are tested and approved. The FDA's recent decision to phase out mandatory animal testing in drug development marks a significant shift in regulatory science. This change, enabled by the FDA Modernization Act 2.0, allows for the use of alternative methods such as organoids, AI-based models, and other human-relevant technologies in preclinical testing U.S. Food and Drug Administration This move is expected to enhance drug safety, reduce research and development costs, and expedite the availability of treatments. By encouraging the submission of non-animal safety data for human trial applications, the FDA aims to modernize the drug evaluation process and reduce the reliance on animal testing Reuters For companies and stakeholders in the pharmaceutical and biotech industries, this development presents an opportunity to align with cutting-edge regulatory practices and contribute to more ethical and efficient drug development processes. 💡 Why This Is a Big Deal 1. Ethical + Scientific Breakthrough Ethical concerns around animal testing have long haunted biotech. NAMs are more human-relevant than animal models—giving better predictions for drug safety/efficacy. 2. Faster, Cheaper, Smarter Animal studies are expensive, slow, and often fail to translate to humans. New approaches can cut preclinical timelines, reduce costs by millions, and get therapies to patients faster. 3. A New Playing Field for Innovation Startups and platforms focused on non-animal preclinical testing now have a strategic edge. Companies developing organ-on-a-chip tech, computational models, and cell-based assays are likely to attract investment and partnerships. Likarda Doug Nissinoff Bill Breitenbach Bullpen Christiaan Engstrom For more detailed information, you can refer to the FDA's official announcement: #FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. https://lnkd.in/eudJWGFT

🐖🧬 Minipigs — A Promising Alternative to NHP Models in future Preclinical Research 𝙀𝙭𝙘𝙞𝙩𝙚𝙙 𝙩𝙤 𝙨𝙝𝙖𝙧𝙚 𝙖𝙣 𝙞𝙢𝙥𝙤𝙧𝙩𝙖𝙣𝙩 𝙨𝙘𝙞𝙚𝙣𝙩𝙞𝙛𝙞𝙘 𝙪𝙥𝙙𝙖𝙩𝙚 𝙛𝙧𝙤𝙢 𝙩𝙝𝙚 𝙜𝙡𝙤𝙗𝙖𝙡 𝙗𝙞𝙤𝙢𝙚𝙙𝙞𝙘𝙖𝙡 𝙘𝙤𝙢𝙢𝙪𝙣𝙞𝙩𝙮. 🔔 The €17.5M EU-funded NHPig project initiative is advancing Minipigs as an ethical and scientifically robust alternative to non-human primates for several preclinical study categories strongly aligned with global 3Rs goals. 💡 𝗪𝗵𝘆 𝗠𝗶𝗻𝗶𝗽𝗶𝗴𝘀? ▪️ Physiological and immune-response similarity to humans ▪️ Strong translational relevance in safety, immunology & biologics ▪️ Lower variability & cost-effective vs traditional large-animal models 🧬 𝗛𝘂𝗺𝗮𝗻𝗶𝘀𝗲𝗱 𝗚ö𝘁𝘁𝗶𝗻𝗴𝗲𝗻 𝗠𝗶𝗻𝗶𝗽𝗶𝗴𝘀 Minipigs genetically engineered to express human 𝗜𝗴𝗚𝟭 / 𝗜𝗴𝗚𝟰 heavy chain and κ-light chain genes have already shown tolerance to human therapeutic antibodies, opening new opportunities for: ☑️ Immunogenicity assessment ☑️ Antibody & biologics evaluation ☑️ Advanced cell & gene therapy safety profiling 🔗 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗼𝗻 𝗵𝘂𝗺𝗮𝗻𝗶𝘀𝗲𝗱 𝗺𝗶𝗻𝗶𝗽𝗶𝗴𝘀: https://lnkd.in/gjKwrUdx 🚀 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲? Studies previously dependent only on NHPs may soon transition to minipigs, providing: ◽ Ethical alternative models ◽ Higher scalability ◽ Strong clinical relevance ◽ Reduced dependency on primates 📘 Also sharing the latest Göttingen Minipigs Magazine – Winter 2025 (attached), featuring insights on the #NHPIGS initiative and scientific advances in minipig research. 🤝 𝗙𝗼𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀, 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 & 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘁𝗲𝗮𝗺𝘀 If you are exploring 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀, 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆, 𝗖𝗔𝗥-𝗧, 𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀, minipig models may significantly accelerate development pathways. If you need any more information, Feel free to message me. Happy to discuss and share insights. #Minipigs #TranslationalResearch #3Rs #NHPReduction #HumanisedMinipigs #BiologicsDevelopment #ImmunotherapyResearch #PreclinicalScience #BiomedicalInnovation #AnimalWelfare Ellegaard Göttingen Minipigs Palamur Biosciences Pvt Ltd